

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Fraser *et al.*
Appl. No.: 10/805,977
Filed: March 22, 2004
For: METHODS FOR TREATING LOWER URINARY TRACT DISORDERS
USING $\alpha_2\delta$ SUBUNIT CALCIUM CHANNEL MODULATORS WITH
SMOOTH MUSCLE MODULATORS

April 2, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document.

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,




Edward R. Ergenzinger, Jr.
Registration No. 47,549

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,
on April 2, 2004


Lynda Jo Pixley

Substitute for form 1449/PTO
(Revised 04/2003)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/805,977
Filing Date March 22, 2004
First Named Inventor Fraser
Group Art Unit Not yet assigned
Examiner Name Not yet assigned
Attorney Docket Number 046562/274660

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-6,531,509 B2	03-11-2003	Singer <i>et al.</i>	
	2	US-6,482,837 B1	11-19-2002	Wood	
	3	US-6,329,429 B1	12-11-2001	Schrier <i>et al.</i>	
	4	US-6,255,526 B1	07-03-2001	Pesachovich <i>et al.</i>	
	5	US-6,054,482	04-25-2000	Augart <i>et al.</i>	
	6	US-5,698,549	12-16-1997	Steers <i>et al.</i>	
	7	US-2004/0037881 A1	02-26-2004	Guittard <i>et al.</i>	
	8	US-2003/0055109 A1	03-20-2003	Singer <i>et al.</i>	
	9	US-2002/0045662 A1	04-18-2002	Singer <i>et al.</i>	
	10	US-2003/0018061 A1	01-23-2003	Ogawa <i>et al.</i>	
	11	US-2002/0032235 A1	03-14-2002	Schrier <i>et al.</i>	
	12	US-2002/0091159 A1	07-11-2002	Spireas	
	13	US-2002/0198136 A1	12-26-2002	Mak <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	14	EP 1 289 364 A1	03-12-2003	Teva Pharmaceutical Industries Ltd.		
	15	WO 02/069906 A2	09-12-2002	Cellegy Pharmaceuticals, Inc.		
	16	WO 02/45711 A1	06-13-2002	Arakis Ltd.		
	17	WO 01/97782 A1	12-27-2001	Teva Pharmaceutical Industries Ltd.		
	18	WO 01/97612 A1	12-27-2001	Teva Pharmaceutical Industries Ltd.		

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 04/2003) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/805,977	
				Filing Date	March 22, 2004	
				First Named Inventor	Fraser	
				Group Art Unit	Not yet assigned	
Examiner Name	Not yet assigned					
Sheet	2	of	2	Attorney Docket Number	046562/274660	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	19	WO 00/67742 A3	11-16-2000	Warner-Lambert Company		
	20	WO 00/61135	10-19-2000	Warner-Lambert Company		
	21	WO 00/50027	08-31-2000	Warner-Lambert Company		
	22	WO 99/59573	11-25-1999	Warner-Lambert Company		
	23	WO 99/59572	11-25-1999	Warner-Lambert Company		
OTHER DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				English Language Translation Attached
	24	HANSEN, H.C., "Interstitial Cystitis and the Potential Role of Gabapentin," <i>Southern Medical Journal</i> , 2000, pp. 238-242, Vol. 93(2).				
	25	MEGSON, I.L., "Nitric Oxide Donor Drugs," <i>Drugs of the Future</i> , 2000, pp. 701-715, Vol. 25(7).				
	26	NILVEBRANT, L., "Tolterodine and its Active 5-Hydroxymethyl Metabolite: Pure Muscarinic Receptor Antagonists," <i>Pharmacology & Toxicology</i> , 2002, pp. 260-267, Vol. 90.				
	27	SEGUCHI, <i>et al.</i> , "Expression of beta 3-Adrenoceptors in Rat Detrusor Smooth Muscle," <i>The Journal of Urology</i> , 1998, pp. 2197-2201, Vol. 159(6).				
	28	TANAKA, N., <i>et al.</i> , "Relationship Between Stereochemistry and the β_3 -Adrenoceptor Agonistic Activity of 4'-Hydroxynorephedrine Derivative as an Agent for Treatment of Frequent Urination and Urinary Incontinence," <i>J. Med. Chem.</i> , 2003, pp. 105-112, Vol. 46.				
	29	WANG, P.S., <i>et al.</i> , "Urinary Antispasmodic Use and the Risks of Ventricular Arrhythmia and Sudden Death in Older Patients," <i>JAGS</i> , 2002, pp. 117-124, Vol. 50.				
Examiner Signature				Date Considered		

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.